CDC Website CDC Website

To Join the NPIN community or

You are here

HIV/AIDS Prevention

Strengthening Combination Prevention and Testing Services among Inmates to Reduce HIV Infections and to Reduce Morbidity and Mortality in the Republic of South Africa under the President's Emergency Plan for AIDS Relief (PEPFAR)

This award will focus on strengthening HIV combination prevention within all correctional facilities in South Africa. Innovative combination prevention interventions will address HIV risk and increase protective behaviors among inmates, accompanied by voluntary medical male circumcision, and HIV Testing Services (HTS). The target populations include inmates, released individuals, and Department of Correctional Services (DCS) staff.

Implementing Evidence-Based Prevention Interventions for Key and Priority Populations in the Republic of Rwanda under the President's Emergency Plan for AIDS Relief (PEPFAR)

The intent of this NOFO is to build on the previous work in implementing evidence-based interventions for HIV prevention, care, and treatment among key populations (KP) and priority populations (PP) in Rwanda including male and female commercial sexual workers (CSWs), men who have sex with men (MSM), and other high-risk individuals.

Technical Assistance to Central Asian National HIV Programs to Achieve and Sustain HIV Epidemic Control under the President's Emergency Plan for AIDS Relief (PEPFAR)

Edith Jickling's picture

This NOFO is for technical assistance to the national HIV programs supported by the CDC Central Asia Regional office under PEPFAR. The technical assistance provider will pilot and evaluate new models of service delivery for 1) accelerating antiretroviral treatment (ART) scale up, adherence, and retention 2) HIV case finding and 3) harm reduction among Key Populations (KP) and PLHIV. Successful models of service delivery and electronic monitoring of patient care will be handed over, scaled up, and sustained by host country government by the end of the five year cooperative agreement.

Modeling and Simulation to Optimize HIV Prevention Research (MS OPR) (R01 Clinical Trial Not Allowed)

The purpose of this Funding Opportunity Announcement (FOA) is to support the development and validation of modeling and simulation methods and related tools to examine HIV transmission dynamics, make epidemic projections, and estimate the impact of HIV treatment and prevention. Investigators are expected to share these resources with other researchers. Funding for the final fourth year is dependent upon achieving applicant-proposed and pre-award negotiated "Go/No-Go criteria".

AIDS Research Center on Mental Health and HIV/AIDS (P30 Clinical Trial Optional)

The National Institute of Mental Health (NIMH) Division of AIDS Research (DAR) encourages applications for Center Core grants (P30) to support an HIV/AIDS Research Center (ARC). The ARC is intended to provide infrastructural support that facilitates the development of high impact science in HIV/AIDS and mental health that is relevant to the NIMH mission.

Sustained Release Innovation for HIV (SRI) (R61/R33 Clinical Trial Optional)

The purpose of this Funding Opportunity Announcement (FOA) is to stimulate the development of new and innovative sustained/extended release drugs and drug delivery systems (DDS) that can achieve extended durations (months to years) of HIV prevention in at-risk individuals. This FOA requires an industry partner, milestones linked to Go/No Go decisions and year 5 funding requires communication with/ pre-IND submission to the FDA.

Investigation of the Transmission of Kaposi Sarcoma-Associated Herpesvirus (KSHV) (R01 Clinical Trial Optional)

The purpose of the funding opportunity announcement (FOA) is to advance our understanding of the modes of transmission of Kaposi sarcoma-associated herpesvirus (KSHV), also called human herpesvirus-8 (HHV-8); the biology of the initial steps of infection; and risk factors for infection to inform efforts to prevent KSHV transmission and thus prevent Kaposi sarcoma (KS), KSHV-associated multicentric Castleman disease (MCD), primary effusion lymphoma (PEL), and other KSHV-induced diseases in populations living with HIV or at high risk of developing HIV.

Pages

Subscribe to RSS - HIV/AIDS Prevention